PRODUCT

Helping urologists make informed treatment decisions with patients

Our tests use reliable AI to analyze pathology slides and predict response to BCG, the standard of care in non-muscle invasive bladder cancer, and prognosticate outcomes

Use Vesta

DATA

Evidence for Vesta

2x

Biomarker-present patients have a 2x elevated risk of non-response to BCG compared to biomarker-absent patients

2x

Patients with high recurrence scores have a 2x elevated risk of recurrence within 6 and 24 months

3x

Patients with high progression scores have a >3x elevated risk of disease progression within 3 years

TESTIMONIALs

The introduction of Vesta has been transformative to my practice. The ability to predict which of my patients won't respond to BCG and route them to an alternative is a paradigm shift in bladder cancer treatment. Its seamless integration into our existing workflows has also been invaluable.

Stephen Williams

Urologist, UTMB

The introduction of Vesta is a paradigm shift for how we can best serve our bladder cancer patients. Its ability to predict response to BCG treatment is invaluable, particularly amidst the current nationwide BCG shortage. This breakthrough allows us to judiciously allocate our limited BCG therapy and responsibly pursue the best option for each patient. This ensures each patient receives personalized and highly effective treatment.

Jay Shah

Urologist, Stanford Health Care

Partnerships

Working with pharma to give patients options

We partner with pharmaceutical companies to run validation studies for new therapies, giving patients more choices if they are unlikely to respond to the standard of care.

Work with us

Partnering with pharma companies to run validation studies for novel cancer therapies

Helping patients get access to novel treatments and trials if BCG isn’t right for them

Improving outcomes and limiting toxicity by helping people  use the most appropriate therapy for their illness

FAQS

Frequently asked questions about Vesta

What is Vesta?

Vesta is Valar Labs' GU-focused portfolio of AI-powered diagnostic test, providing deep insights into each patient's unique disease using routine histology. Vesta tests are currently available in bladder cancer, with other indications in development.

Who is Vesta intended for?

Vesta Bladder tests are intended for patients with non-muscle invasive bladder cancer. Vesta Bladder Risk Stratify provides individualized risks of disease recurrence and progression, and Vesta Bladder BCGPredict is the only bladder cancer diagnostic that predicts treatment response to BCG, through histology alone.

How much does Vesta testing cost?

Valar Labs is committed to providing patient access regardless of finances. Our Financial Access Program supports patients with financial needs.

What is the turnaround time for the test?

You can expect Vesta Bladder test results back within approximately 3 days after the sample has arrived at our laboratory.

How can I order Vesta testing?

Vesta Bladder testing is offered through licensed physicians who treat patients with bladder cancer. Vesta tests are performed in Valar Labs' CLIA-certified laboratory.

Do I need an additional sample to run Vesta?

No, Vesta Bladder testing uses an existing sample from routine procedures already performed to diagnose bladder cancer. No additional procedure or sample collection is needed.

When is Vesta ordered in my diagnostic process?

Vesta Bladder testing can be ordered after a bladder cancer diagnosis is made to help clinical management planning.

News & Resources

Latest News

Artificial Intelligence Biomarkers Predict Poor Efficacy of Bacillus Calmette-Guérin Rechallenge in Previously Bacillus Calmette-Guérin–Treated Nonmuscle-Invasive Bladder Cancer

Journal of Urology
July 2025

Artificial Intelligence Biomarkers Predict Poor Efficacy of Bacillus Calmette-Guérin Rechallenge in Previously Bacillus Calmette-Guérin–Treated Nonmuscle-Invasive Bladder Cancer

Journal of Urology
July 2025

Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer

Businesswire
June 2025

Valar Labs’ CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer

Businesswire
June 2025

Computational Histology Artificial Intelligence Enhances Risk Stratification of High-grade Ta Non–muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current EAU and AUA Stratification Schemes

European Urology
June 2025

Computational Histology Artificial Intelligence Enhances Risk Stratification of High-grade Ta Non–muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current EAU and AUA Stratification Schemes

European Urology
June 2025